UA92782C2 - Новый поверхностный белок haemophilus influenzae (белок е; ре) - Google Patents

Новый поверхностный белок haemophilus influenzae (белок е; ре)

Info

Publication number
UA92782C2
UA92782C2 UAA200810445A UAA200810445A UA92782C2 UA 92782 C2 UA92782 C2 UA 92782C2 UA A200810445 A UAA200810445 A UA A200810445A UA A200810445 A UAA200810445 A UA A200810445A UA 92782 C2 UA92782 C2 UA 92782C2
Authority
UA
Ukraine
Prior art keywords
protein
surface exposed
haemophilus influenzae
novel surface
nucleic acid
Prior art date
Application number
UAA200810445A
Other languages
English (en)
Ukrainian (uk)
Inventor
Арне Форсгрен
Кристиан Риесбекк
Original Assignee
Арне Форсгрен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арне Форсгрен filed Critical Арне Форсгрен
Publication of UA92782C2 publication Critical patent/UA92782C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Данное изобретение относится к поверхностному белку, выявленному вкоторый имеет аминокислотную последовательность SEQ I D NO: 1, или его фрагмент, где указанный фрагмент содержит аминокислотную последовательность, которая имеет, по меньшей мере, 15 последовательных аминокислот из аминокислотной последовательности SEQ ID N0:1, указанный фрагмент (при необходимости всочетании с носителем) способен индуцировать иммунный ответ, который распознает полипептид SEQ ID N0:1. Также описаны композиции вакцин, которые содержат аминокислотные последовательности SEQ ID N0:1-10.
UAA200810445A 2006-01-17 2007-01-17 Новый поверхностный белок haemophilus influenzae (белок е; ре) UA92782C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75898706P 2006-01-17 2006-01-17

Publications (1)

Publication Number Publication Date
UA92782C2 true UA92782C2 (ru) 2010-12-10

Family

ID=38287906

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810445A UA92782C2 (ru) 2006-01-17 2007-01-17 Новый поверхностный белок haemophilus influenzae (белок е; ре)

Country Status (20)

Country Link
US (5) US8617565B2 (ru)
EP (1) EP1973933B1 (ru)
JP (3) JP5275814B2 (ru)
KR (2) KR20080096775A (ru)
CN (2) CN104436180B (ru)
AU (1) AU2007206114B2 (ru)
BR (1) BRPI0707154B8 (ru)
CA (1) CA2636566C (ru)
EA (1) EA015561B1 (ru)
ES (1) ES2809167T3 (ru)
IL (2) IL192674B (ru)
MA (1) MA30309B1 (ru)
MX (1) MX2008009280A (ru)
MY (1) MY150105A (ru)
NO (1) NO346497B1 (ru)
NZ (1) NZ569417A (ru)
SG (2) SG10201600336RA (ru)
UA (1) UA92782C2 (ru)
WO (1) WO2007084053A1 (ru)
ZA (1) ZA200805602B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP1913019B1 (en) 2005-08-10 2014-12-31 Arne Forsgren AB Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
ES2809167T3 (es) * 2006-01-17 2021-03-03 Forsgren Arne Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
BR112013029024A2 (pt) * 2011-05-11 2017-10-31 Riesbeck Healthcare Sweden Ab proteína f - uma nova adesina de haemophilus influenzae com propriedades de ligação à laminina e vitronectina
EA201590491A1 (ru) * 2012-10-17 2016-01-29 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
BR112019020209A2 (pt) 2017-03-31 2020-06-02 Glaxosmithkline Intellectual Property Development Limited Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação.
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
US11723966B2 (en) 2017-08-14 2023-08-15 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CN108037277A (zh) * 2017-12-07 2018-05-15 中国兽医药品监察所 一种区分牛布鲁氏菌疫苗免疫与自然感染状态的方法
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CA3136691A1 (en) * 2019-04-12 2020-10-15 Geltor, Inc. Recombinant elastin and production thereof
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
EP4009951A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Process for preparing a composition comprising a protein d polypeptide
BR112021026565A2 (pt) 2019-08-05 2022-05-03 Glaxosmithkline Biologicals Sa Composição imunogênica
JP2024510717A (ja) 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0449856B1 (en) 1988-12-16 2001-09-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
JP3215109B2 (ja) 1991-02-15 2001-10-02 ユーエイビー リサーチ ファウンデーション 肺炎球菌タンパクの構造遺伝子
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
WO1994022914A1 (en) 1993-04-06 1994-10-13 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
EP1300156A3 (en) 1993-05-18 2003-05-07 The Ohio State University Research Foundation Otitis media vaccine
AU683073B2 (en) 1993-06-07 1997-10-30 Amgen, Inc. Hybrid receptor molecules
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2717081B1 (fr) 1994-03-14 1996-06-21 Centre Nat Rech Scient Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
PL323781A1 (en) 1995-06-07 1998-04-27 Biochem Vaccines Inc Streptococco thermal shock proteins belonging to a family hsp70
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
ATE323721T1 (de) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
WO1998018931A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
CA2292838A1 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
US6764686B2 (en) 1997-07-21 2004-07-20 Baxter International Inc. Modified immunogenic pneumolysin compositions as vaccines
NZ530277A (en) 1998-04-07 2005-08-26 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
CA2328399A1 (en) 1998-04-23 1999-10-28 University Of Alabama At Birmingham Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
MY125387A (en) * 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0003502D0 (en) 2000-02-15 2000-04-05 Smithkline Beecham Sa Vaccine
MY133981A (en) * 2000-06-29 2007-11-30 Smithkline Beecham Biologicals S A Vaccine composition
JP2004509647A (ja) * 2000-10-02 2004-04-02 シャイアー・バイオケム・インコーポレイテッド ヘモフィルス・インフルエンゼ抗原及び対応ｄｎａ断片
GB0025171D0 (en) 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
GB0025170D0 (en) 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
GB0025998D0 (en) 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
ES2809167T3 (es) 2006-01-17 2021-03-03 Forsgren Arne Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE)
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
EA015561B1 (ru) 2011-08-30
IL259316B (en) 2022-10-01
NO346497B1 (no) 2022-09-05
EA200870176A1 (ru) 2009-06-30
IL259316B2 (en) 2023-02-01
US8617565B2 (en) 2013-12-31
US20090246219A1 (en) 2009-10-01
EP1973933A1 (en) 2008-10-01
ES2809167T3 (es) 2021-03-03
KR20080096775A (ko) 2008-11-03
US20170326223A1 (en) 2017-11-16
JP6008747B2 (ja) 2016-10-19
JP5275814B2 (ja) 2013-08-28
KR101737464B1 (ko) 2017-05-18
SG175492A1 (en) 2011-11-28
CA2636566C (en) 2018-03-13
CN104436180A (zh) 2015-03-25
US9309293B2 (en) 2016-04-12
JP2009523790A (ja) 2009-06-25
CN101374859A (zh) 2009-02-25
US20150071956A1 (en) 2015-03-12
MA30309B1 (fr) 2009-04-01
US20140350220A1 (en) 2014-11-27
IL259316A (en) 2018-07-31
CA2636566A1 (en) 2007-07-26
IL192674B (en) 2018-08-30
EP1973933B1 (en) 2020-06-24
NO20082827L (no) 2008-10-17
AU2007206114A1 (en) 2007-07-26
BRPI0707154B1 (pt) 2019-05-07
JP2016135770A (ja) 2016-07-28
JP2013126986A (ja) 2013-06-27
US20160114021A1 (en) 2016-04-28
MY150105A (en) 2013-11-29
WO2007084053A1 (en) 2007-07-26
AU2007206114B2 (en) 2013-01-24
CN101374859B (zh) 2014-11-26
CN104436180B (zh) 2021-08-31
MX2008009280A (es) 2008-12-12
ZA200805602B (en) 2009-12-30
EP1973933A4 (en) 2010-04-07
SG10201600336RA (en) 2016-02-26
NZ569417A (en) 2012-04-27
US11400148B2 (en) 2022-08-02
BRPI0707154B8 (pt) 2022-12-20
KR20140101387A (ko) 2014-08-19
BRPI0707154A2 (pt) 2011-04-26
IL192674A0 (en) 2009-02-11
US9744225B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
MY150105A (en) A novel surface exposed haemophilus influenzae protein (protein e; pe)
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
UA98620C2 (ru) Аттенуированный вирус классической лихорадки свиней, содержащий модифицированный гликопротеин е2
WO2001031019A3 (en) Neisserial antigenic peptides
JP2006149406A5 (ru)
NZ570553A (en) Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines
JP2006187292A5 (ru)
EP3552622A3 (en) Priming of an immune response
NZ591415A (en) Haemophilus influenzae type B
JP2006501825A5 (ru)
JP2013517783A5 (ru)
UA107329C2 (ru) Туберкулезный белок rv2386c, композиция, содержащая его, и применения
WO2011146933A3 (en) Universal dengue virus sequences and methods of use
WO2008127179A8 (en) Fusion protein vaccine
UA107330C2 (ru) Туберкулезный белок rv3616c и его применение
JP2012515557A5 (ru)
TW200716166A (en) Lawsonia intracellularis immunological proteins
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2003066820A3 (en) Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
WO2006113782A3 (en) Lawsonia protein useful as a component in subunit vaccine and methods of making and using thereof
MX2009003188A (es) Polipeptidos hibridos inmunogenicos antiobesidad y composicion de vacuna antiobesidad que comprende los mismos.
ATE466876T1 (de) Immunogene konstrukte
PT1962889E (pt) Polipéptido imunogénico formado por péptidos crípticos optimizados provenientes de antigénios tumorais, e suas utilizações